<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4850">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01884402</url>
  </required_header>
  <id_info>
    <org_study_id>FPS-PEG-2010-01</org_study_id>
    <nct_id>NCT01884402</nct_id>
  </id_info>
  <brief_title>Observational,Prospective Study to Develop and Validate a Prognostic Tool to Optimize Therapy in Patients With HCV G1/4</brief_title>
  <acronym>OPTIM</acronym>
  <official_title>Observational,Post-authorization Prospective Study to Develop and Validate a Prognostic Tool for Optimizing Therapy in Patients With Hepatitis C Virus (HCV) Genotype 1 and 4.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</source>
  <oversight_info>
    <authority>Spain: Ethics Committee</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:

      • Develop and validate a tool towards patients with chronic hepatitis C genotype 1 and 4 to
      allow optimize treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Tool:

        1. Predicting the overall impact of prognostic factors (including the new factor of
           genetic polymorphism of the IL28B) on Sustained Viral Response (SVR).

        2. Identify those patients most likely to respond.

        3. Therapy and therefore optimize resources

      The validation tool will check into clinical practice its predictive power (it will consider
      its ability to calibrate and discriminate) and make correct inferences and interpretations
      of the scores obtained when applying.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Sustained Viral Response (RVS)</measure>
    <time_frame>1 ½ years (72 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement of HCV RNA negativization 24 weeks after treatment</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">770</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Pegasys, injection subcutaneous</arm_group_label>
    <description>HCV patients monoinfected or coinfected genotype 1/4 treated with Peginterferon alfa-2a and Ribavirin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a</intervention_name>
    <description>Treatment as usual clinical practice</description>
    <arm_group_label>Pegasys, injection subcutaneous</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Treatment as usual clinical practice</description>
    <arm_group_label>Pegasys, injection subcutaneous</arm_group_label>
    <other_name>Copegus</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic hepatitis C genotype 1 and 4 mono-or co-infected with HIV who meet
        the selection criteria described.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with &gt; 18 years old.

          -  Patients diagnosed with chronic hepatitis C in the presence of HCV RNA in plasma that
             meet criteria for initiating antiviral therapy in routine clinical practice
             conditions.

          -  Patients Genotype 1 and 4.

          -  Patients with the results of all the factors evaluable at the time of inclusion.

          -  Patients who have accepted their participation in the study through informed consent.

        Exclusion Criteria:

          -  Patients previously treated with interferon (IFN) and ribavirin (RBV).

          -  Patients with genotype 2, 3, 5 and 6.

          -  Patients with co-infection with hepatitis B.

          -  Patients with other liver diseases.

          -  Patients with any contraindications to the drugs used in the treatment of hepatitis
             C.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel Romero-Gómez, Medicine</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Valme &amp; ciberEHD</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manuel Romero- Gomez, Medicine</last_name>
    <email>mromerogomez@us.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fundación Pública Andaluza para la Gestión de la investigación en salud de Sevilla (FISEVI)</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>FISEVI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundación Pública Andaluza para la Gestión de la investigación en salud de Sevilla (FISEVI)</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 20, 2013</lastchanged_date>
  <firstreceived_date>June 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
